Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 in Combination With Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
NCT07331155Phase 2Recruiting
- Sponsor
- Leads Biolabs
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Leads Biolabs. Started Feb 2026; status: recruiting.
02
Drugs
opamtistomig
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07331155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331155.